✨ Unlock Data Exports And Disclosure Access.Start Your 30-Day Free Trial Today →

Kalbe Farma Tbk PT

Common Name
Kalbe Farma
Country
Indonesia
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
12,784
Ticker
KLBF
Exchange
Indonesia Stock Exchange
Description
Kalbe Farma Tbk. PT is a prominent pharmaceutical corporation in Indonesia known for its extensive range of healthcare products and services. As a leader in the pharmaceutical industry, its primary fu...

Kalbe Farma's GHG Emissions Data Preview

In 2024, Kalbe Farma completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).

However, Kalbe Farma has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.

Metric (tCO2e)2024202320222021-2019
Total Scope 1
19,895.14a
18,484.77a
24,392.2a
Total Scope 2
Unspecified Calculation Method
82,970.35a
75,530.4a
97,934.59a
Total Scope 3
4.6a
N/AN/A
Total Scope 1 Revenue Intensity (tCO2e/$M)
9.8084a
9.3641a
13.1683a
Usage Policy

You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"

Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.

Access Datasets, Disclosures, and Sources
pro
Remove manual data sourcing from your workflow. Subscribe to Tracenable Pro to get credits for accessing and exporting datasets and disclosures across 8,500+ companies with 10+ years of historical coverage.
Download granular datasets (CSV/XLS)
Access underlying corporate disclosures (PDF)
Trace all values back to their original sources
Formats Included
Excel
CSV
Json
All data fully traceable to original sources
Used by 1,000+ teams in finance, climate, and research
Access this data via API
$curl "https://tracenable.com/api/v1/ghg-emissions/absolute?ticker=KLBF&reporting_period=2024"

Verified Sources Behind Kalbe Farma’s Greenhouse Gas (GHG) Emissions Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.

a. Kalbe Farma's Sustainability Report 2024
b. Kalbe Farma's Sustainability Report 2022

Insights into Kalbe Farma's Operational Emissions

In 2024, the total operational greenhouse gas (GHG) emissions of Kalbe Farma amounted to 102,865.49 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a

Compared to 2023, the total operational greenhouse gas (GHG) emissions of Kalbe Farma increased by 9.41%, suggesting that the company faced challenges in reducing its emissions from its core operations.a

Kalbe Farma's Scope 1 Emissions Over Time

2020202120222023202406.5 k13 k19.5 k26 ktCO2e+47%+17%-24%+8%
  • Total Scope 1
  • Year-over-Year Change

What are Kalbe Farma's Scope 1 emissions?

In 2024, the total Scope 1 emissions of Kalbe Farma were 19,895.14 metric tons of CO₂ equivalent (tCO₂e).a

Has Kalbe Farma reduced its Scope 1 emissions over time?

Since 2020, Kalbe Farma's Scope 1 emissions have increased by 39.78%, reflecting a rising long-term trend in Scope 1 emissions over time.ab

Compared to the previous year (2023), Kalbe Farma's Scope 1 emissions increased by 7.63%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.a

What are Kalbe Farma's Scope 2 emissions?

In 2024, Kalbe Farma reported Scope 2 greenhouse gas (GHG) emissions of 82,970.35 tCO₂e without specifying the calculation method.a

Has Kalbe Farma reduced its Scope 2 emissions over time?

Since 2020, Kalbe Farma's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have increased by 30.2%, reflecting a rising long-term trend in Scope 2 emissions over time.ab

Compared to the previous year (2023), Kalbe Farma's Scope 2 emissions (Unspecified Calculation Method) have remained relatively stable, indicating that Kalbe Farma's emissions have plateaued with no significant change in its energy consumption footprint.a

What methodology does Kalbe Farma use for Scope 2 reporting?

In 2024, Kalbe Farma reported its Scope 2 emissions using an unspecified methodology.a

Kalbe Farma's Scope 2 Emissions Over Time

20202021202220232024025 k50 k75 k100 ktCO2e
  • Total Scope 2 (Unspecified Calculation Method)

Insights into Kalbe Farma's Value Chain Emissions

In 2024, Kalbe Farma reported 4.6 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a

The 2024 disclosure of Kalbe Farma includes a breakdown across 0 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2023, demonstrating consistent Scope 3 emissions reporting coverage year over year.a

Kalbe Farma's Scope 3 Emissions Over Time

202402468tCO2e
  • Total Scope 3
  • Year-over-Year Change

What are Kalbe Farma's Scope 3 emissions?

In 2024, Kalbe Farma reported total Scope 3 emissions of 4.6 metric tons of CO₂ equivalent (tCO₂e).a

Insights into Kalbe Farma’s GHG Emissions Intensity Compared to Industry Peers

In 2024, Kalbe Farma reported Scope 1 greenhouse gas (GHG) emissions of 19,895.14 tCO₂e and total revenues of USD 2,028 millions. This translates into an emissions intensity of 9.81 tCO₂e per millions USD.a

Kalbe Farma's Scope 1 Emissions Intensity Compared to Peers

5005,00050,0001,000,00010,000,000Scope 1 Emissions (tCO2e)1005005,00050,000200,000Revenues (Millions of USD)Daiichi SankyoYear: 2024Scope 1: 91,836 tCO2eRevenue: $M 10,576Scope 1 Intensity: 8.68 tCO2e/$MBayerYear: 2025Scope 1: 1,890,000 tCO2eRevenue: $M 53,581Scope 1 Intensity: 35.27 tCO2e/$MChugai PharmaceuticalYear: 2024Scope 1: 51,143 tCO2eRevenue: $M 7,456Scope 1 Intensity: 6.86 tCO2e/$MGSKYear: 2024Scope 1: 521,000 tCO2eRevenue: $M 39,374Scope 1 Intensity: 13.23 tCO2e/$MBristol-Myers SquibbYear: 2024Scope 1: 206,726 tCO2eRevenue: $M 48,300Scope 1 Intensity: 4.28 tCO2e/$MPfizerYear: 2024Scope 1: 613,218 tCO2eRevenue: $M 63,627Scope 1 Intensity: 9.64 tCO2e/$MGilead SciencesYear: 2024Scope 1: 53,856 tCO2eRevenue: $M 28,754Scope 1 Intensity: 1.87 tCO2e/$MAmgenYear: 2024Scope 1: 147,000 tCO2eRevenue: $M 33,424Scope 1 Intensity: 4.40 tCO2e/$MNovo NordiskYear: 2025Scope 1: 120,000 tCO2eRevenue: $M 48,646Scope 1 Intensity: 2.47 tCO2e/$MAstraZenecaYear: 2024Scope 1: 125,386 tCO2eRevenue: $M 54,074Scope 1 Intensity: 2.32 tCO2e/$MNovartisYear: 2024Scope 1: 207,000 tCO2eRevenue: $M 40,180Scope 1 Intensity: 5.15 tCO2e/$MMerck & Co IncYear: 2024Scope 1: 721,200 tCO2eRevenue: $M 64,168Scope 1 Intensity: 11.24 tCO2e/$MRoche HoldingYear: 2025Scope 1: 211,962 tCO2eRevenue: $M 79,968Scope 1 Intensity: 2.65 tCO2e/$MAbbvieYear: 2025Scope 1: 304,649 tCO2eRevenue: $M 61,160Scope 1 Intensity: 4.98 tCO2e/$MJohnson & JohnsonYear: 2024Scope 1: 314,690 tCO2eRevenue: $M 88,820Scope 1 Intensity: 3.54 tCO2e/$MEli Lilly and CoYear: 2024Scope 1: 192,000 tCO2eRevenue: $M 45,043Scope 1 Intensity: 4.26 tCO2e/$MCosmo PharmaceuticalsYear: 2024Scope 1: 5,658 tCO2eRevenue: $M 278Scope 1 Intensity: 20.38 tCO2e/$MVirbacYear: 2025Scope 1: 13,266 tCO2eRevenue: $M 1,722Scope 1 Intensity: 7.70 tCO2e/$MSanten PharmaceuticalYear: 2024Scope 1: 17,372 tCO2eRevenue: $M 1,994Scope 1 Intensity: 8.71 tCO2e/$MOno PharmaceuticalYear: 2024Scope 1: 8,100 tCO2eRevenue: $M 3,319Scope 1 Intensity: 2.44 tCO2e/$MSichuan Kelun PharmaceuticalYear: 2024Scope 1: 2,361,763 tCO2eRevenue: $M 2,989Scope 1 Intensity: 790.21 tCO2e/$MOrion OyjYear: 2025Scope 1: 5,018 tCO2eRevenue: $M 2,221Scope 1 Intensity: 2.26 tCO2e/$MRecordatiYear: 2025Scope 1: 36,557 tCO2eRevenue: $M 3,078Scope 1 Intensity: 11.88 tCO2e/$MZhangzhou Pientzehuang PharmaceuticalYear: 2023Scope 1: 2,301 tCO2eRevenue: $M 1,415Scope 1 Intensity: 1.63 tCO2e/$MKalbe FarmaYear: 2024Scope 1: 19,895 tCO2eRevenue: $M 2,028Scope 1 Intensity: 9.81 tCO2e/$M

How does Kalbe Farma's GHG emissions intensity compare to its peers?

In 2024, Kalbe Farma reported a Scope 1 emissions intensity of 9.81 tCO₂e per millions USD. Compared to the peer group median of 5.07, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a

Where does Kalbe Farma rank on GHG emissions intensity within its industry?

In 2024, Kalbe Farma ranked 19 out of 24 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a

Kalbe Farma is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a

Insights into Kalbe Farma's Total Carbon Footprint

In 2024, Kalbe Farma reported a total carbon footprint of 102,870.09 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 9.42% increase compared to 2023, suggesting a rise in emissions across its operations or value chain.a

The largest contributor to Kalbe Farma's total carbon footprint was Scope 2 emissions, accounting for 80.66% of the company's total carbon footprint, followed by Scope 1 emissions at 19.34%.a

Want Full Access to Kalbe Farma's GHG Emissions Dataset?
Start 30-Day Free Trial